Next Article in Journal / Special Issue
Biomarkers for Basal-like Breast Cancer
Previous Article in Journal
Molecular Mechanisms Involved in the Antitumor Activity of Cannabinoids on Gliomas: Role for Oxidative Stress
Previous Article in Special Issue
Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies
Open AccessReview

Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies

Laboratory of Hematology-Oncology, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy
Author to whom correspondence should be addressed.
Cancers 2010, 2(2), 1027-1039;
Received: 29 March 2010 / Revised: 11 May 2010 / Accepted: 27 May 2010 / Published: 28 May 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for therapy. Strategies have been pursued to inhibit neovascularization and to destroy existing tumor vessels, or both. These include direct targeting of endothelial cells, and indirect targeting by inhibiting the release of proangiogenic growth factors by cancer or stromal cells. Many patients benefit from antiangiogenic therapies; thus, development of noninvasive biomarkers of disease response and relapse is a crucial objective to aid in their management. A number of non-invasive tools are described with their potential benefits and limitations. We review currently available candidate biomarkers of anti-angiogenic agent effect. Including these markers into clinical trials may provide insight into appropriate dosing for desired biological effects, appropriate timing of additional therapy, and prediction of individual response. This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various other diseases. View Full-Text
Keywords: cancer; angiogenesis; biomarkers cancer; angiogenesis; biomarkers
MDPI and ACS Style

Rabascio, C.; Bertolini, F. Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies. Cancers 2010, 2, 1027-1039.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop